In another study, 14 patients with advanced solid tumours and lymphomas were enrolled in a first-in-human phase I clinical trial using bardoxolone methyl, a semi-synthetic NRF2 inducer, and were screened for NQO1 transcript levels in PBMCs isolated from blood samples collected before and post-treatment [73]. This evidence concerns the gene NFE2L2 and lymphoma.